Roman Franklin was named Chief Financial Officer of Vivos Therapeutics, Inc., succeeding Bradford Amman, effective July 31, 2026. As of November 6, 2026, Vivos Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 3, 2026, naming 1 appointment and 1 departure (Form 8-K, August 3, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Vivos Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Vivos Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-03. It names 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Vivos Therapeutics, Inc. files it.
Also on the record for Vivos Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 19, 2026 | Acquired Series C Preferred | — | Acquisition | Source |
| September 3, 2026 | Stake report, Schedule 13G/A, by Streeterville Capital LLC | 0.6% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| August 11, 2026 | Stake report, Schedule 13G, by Streeterville Capital LLC | 9.3% of the class | 5%+ stakes | Source |
| July 15, 2026 | Stake report, Schedule 13D, by V-Co Investors 4 LLC | 19.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 8.27% of the class | 5%+ stakes | Source |
| April 2, 2026 | Stake report, Schedule 13D, by V-Co Investors 3 LLC | 19.9% of the class | 5%+ stakes | Source |
| July 14, 2025 | Stake report, Schedule 13G, by Dawei Luo | 8.52% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Vivos Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Vivos Therapeutics, Inc. and the records around it.
Vivos Therapeutics, Inc. elsewhere on the record
- Acquisition Oct 2026
- 5%+ stake filings Sep 2026
- Who owns it
Companies that share a holder
- Streeterville Capital LLC also filed stake reports on 29 other companies: Professional Diversity Network, Inc. (Oct 2026), Solowin Holdings, Ltd. (Oct 2026), Empery Digital Inc. (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Vivos Therapeutics, Inc.
Get an email when Vivos Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vivos Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Vivos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vivos Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-03 | Out | Chief Financial Officer | 8-K, 2026-08-03 | ||
| 2026-08-03 | In | Chief Financial Officer | 2026-07-31 | 8-K, 2026-08-03 |
Who leads Vivos Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Bradford Amman, departure reported (filed 2026-08-03). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Vivos Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Vivos Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Vivos Therapeutics, Inc.Every change, in the filing's words
Departing: Bradford Amman, Chief Financial Officer
On July 31, 2026, Bradford Amman resigned as Chief Financial Officer and Secretary of the Company, and from all other officer and committee positions held by reason of his employment, effective as of that date.
Appointed: Roman Franklin, Chief Financial Officer, effective 2026-07-31
Effective July 31, 2026, the Board appointed Roman Franklin, age 42, as the Company's Chief Financial Officer, and designated Mr. Franklin as the Company's principal financial officer for purposes of the Securities Exchange Act of 1934, as amended.
- Mr. Amman's resignation was voluntary and mutually agreed with the Company, and did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices, including any matters concerning the Company's accounting, financial reporting, internal controls or disclosure.
- To support an orderly transition, Mr. Amman will remain with the Company as a non-executive transition employee for a period of ninety (90) days following July 31, 2026 (the "Transition Period"), during which he will serve as the Company's principal accounting officer, and will thereafter serve as an advisor to the Company as an independent contractor for an additional one hundred eighty (180) days (the "Advisory Period").
- The payments and benefits under the Separation Agreement are provided in lieu of any severance or other termination-related payments or benefits under Mr. Amman's employment agreement.
- Mr. Amman will continue to serve as the Company's principal accounting officer during the Transition Period.
- Upon the conclusion of the Transition Period, the Board expects to designate a successor principal accounting officer.
- Pursuant to the MSA, Mr. Franklin serves as the Company's Chief Financial Officer and engagement lead, and CFO Portal provides managed chief financial officer and finance-and-accounting leadership services to the Company.
Tools for this story
Each opens in a new tab, filled in for Vivos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.